To view or add a comment, sign in Novo Nordisk has received CDSCO approval for its blockbuster drug Ozempic, completing its semaglutide portfolio in India as the obesity-treatment market expands rapidly Sanket Koul reports #NovoNordisk #Ozempic #Obesity #WeightLoss #Pharma To view or add a comment, sign in The US FDA is set to decide on Novo Nordisks new drug application for oral semaglutide 25 mg for chronic weight management in adults living with obesity or overweight later this year
While people expect something simple, they get instead of variation, and that variation can make them think something is wrong when everything is going exactly as it should
Data availability All data supporting the findings described in this manuscript are available in the article and in the Supplementary Information
The clinical research cited in NativePath's content (Knig et al
As regards antral length, the current results revealed a significant increase in antral length in the patients who received KD with L-carnitine supplementation after intervention in comparison to the time of enrolment, while there was no significant change noticed in the non-supplemented group
